Tetra Bio-Pharma Inc.
TBP
Rangering i aksjer
#35445
Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical... Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
Aksjekurs
$0.01851783
Sist synkronisert: 2023-05-23
Markedsverdi
$3.71M
Endring (1 dag)
-0.04%
Endring (1 år)
1,443.15%
Land
CA
Handel Tetra Bio-Pharma Inc. (TBP)
Kategori
Healthcare
Utbytteavkastning for Tetra Bio-Pharma Inc. (TBP)
Tetra Bio-Pharma Inc. (aksjesymbol: TBP) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Tetra Bio-Pharma Inc. (TBP) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
